Leadership Signals The company recently appointed Nicholas Opie as Non-Executive Director and strategic advisor, signaling board-level focus on advancing the neuroelectric signal platform. This leadership shift creates openings for high-level introductions to research institutions, healthcare partners, and potential licensing or co-development deals that could accelerate sales.

Product Momentum Oskol 2 expands platform reach by targeting the 13-inch iPad Air with Hiru eye-tracker, while The Block adds AAC pages designed for auditory scanners and individuals with significant visual impairments. Together with the NeuroNode sixth-generation CHI, this strengthens the value proposition for rehab clinics, speech-language pathologists, schools, and assistive-technology distributors to win new accounts or upsell existing ones. The EMG-based NeuroStrip line in development points to adjacent markets suitable for pilots and demonstrations.

Market Engagement Active market engagement through events like the Closing The Gap Conference and ongoing product introductions indicates a robust lead-generation channel. Proactively pursuing demos, speaking engagements, and sponsorships at such conferences can accelerate outreach to clinicians, caregivers, and procurement teams.

Growth Readiness Financials show revenue in the low to mid single digits and a modest funding position, with a lean team of 11-50 employees. This suggests an opportunity to scale via channel partnerships, distributors, or licensing deals with larger manufacturers to extend reach beyond current footprints while maintaining cost discipline.

Target Verticals Core addressable segments are individuals with complex communication needs who benefit from dedicated speech-generating devices and AAC accessories. Beyond primary devices, opportunities exist in health diagnostics, rehabilitation, and sport through EMG NeuroStrip research, offering potential collaboration with research centers and patient advocacy groups to validate ROI and drive procurement.